Individuals with spinal cord injury have heart attacks and strokes more frequently, and much earlier in life. People with spinal cord injuries develop plaque in vessels much faster, and the reasons why are unclear. Doctors generally attributed the increased risk with weight gain and developing diabetes, but many studies have shown that even without these common factors, plaque in vessels is developing more often and faster. Endothelial cells are a single layer of cells that line all vessels in the body and plays an important role in vessel health. Damage to endothelial cells is known to lead to heart attacks and strokes. Past studies on endothelial cells of people with spinal cord injury have been unclear. The investigators have new data that these cells are unhealthy after spinal cord injury a measurement. This includes measuring endothelial health by directly altering its function using a catheter in the arm and measuring small particles in blood called endothelial microvesicles. If the project is successful, the investigators will learn important information on the health of endothelial cells after spinal cord injury. The investigators will also be able to use these markers of endothelial cell function to create treatments to improve vessel health and prevent heart attacks and strokes later in life in people with spinal cord injury.

开始日期2024-06-01

申办/合作机构

Craig Hospital

[+1]

NCT06043310 / RecruitingN/A

Sex-specific Effects of Continuous Estrogen on Human in Vivo Microvascular Function

The goal of this study is to learn how long-term use of estrogen affects blood vessels in healthy adults who were assigned male at birth.
Participants will:
give one blood draw of 5 mL
have a camera placed under the tongue to take pictures of blood vessels
have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion
Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

开始日期2023-06-02

申办/合作机构

The Medical College of Wisconsin, Inc.

ACTRN12623000467639 / Not yet recruiting临床1期

Dose response of afterload reduction with sodium nitroprusside on left ventricular filling pressure under veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support in adults

开始日期2023-06-01

申办/合作机构

Sydney Local Health District

100 项与硝普钠相关的临床结果

登录后查看更多信息

100 项与硝普钠相关的转化医学

登录后查看更多信息

100 项与硝普钠相关的专利（医药）

登录后查看更多信息

13,569

项与硝普钠相关的文献（医药）

2024-04-01·Journal of ethnopharmacology

Danhong formula alleviates endothelial dysfunction and reduces blood pressure in hypertension by regulating MicroRNA 24 - Phosphatidylinositol 3-Kinase-Serine/Threonine Kinase- Endothelial Nitric Oxide Synthase axis

Article

作者: Yang, Xiaohu ; Ye, He ; He, Shuang ; Lei, Shanshan ; Yang, Wenchao

ETHNOPHARMACOLOGICAL RELEVANCE:

Essential hypertension (EH) is one of the important risk factors of cardio-cerebrovascular diseases, and it can significantly increase the incidence and mortality of acute myocardial infarction, cerebral infarction and hemorrhage. Danhong Formula (DHF) was consisting of Radix et Rhizoma Salviae Miltiorrhizae (Salvia miltiorrhiza Bge., Labiatae, Danshen in Chinese) and Flos Carthami (Carthamus tinctorius L., Compositae, Honghua in Chinese) (Plant names have been checked with http://www.the plant list.org on June 28th, 2023) was approved by State Food and Drug Administration of China, that has been used for thousands of years in the treatment of cardiovascular diseases in China with proven safety and efficacy. Though our previous studies have found that DHF improved endothelial dysfunction (ED) and decreased high blood pressure (BP), the underlying mechanisms of its antihypertensive effect still remain unclear.

AIM OF THE STUDY:

This study investigated whether DHF regulated MicroRNA 24- Phosphatidylinositol 3-Kinase-Serine/Threonine Kinase- Endothelial Nitric Oxide Synthase (miR-24 - PI3K/AKT/eNOS) axis to produce antihypertensive effect and improve endothelial dysfunction.

MATERIALS AND METHODS:

Firstly, the chemical components of DHF were analyzed by UHPLC-MS. After that, BP was continuously monitored within the 1st, 3rd, and 4th week in SHR to evaluate the antihypertensive effect of DHF intraperitoneal injection. In addition, not only the contents of serum nitric oxide (NO), prostacyclin (PGI₂), and angiotensin II (Ang II) were detected, but also the isolated aorta ring experiment was conducted to evaluate the vasomotoricity to evaluate of DHF on improving endothelial dysfunction. Key proteins or mRNA expression associated with miR-24 - PI3K/AKT/eNOS axis in aorta were detected by capillary Western blot, immunohistochemistry or RT-PCR to explore the underlying mechanisms. Index of NO, Ang II PGI₂ and key proteins or mRNA expression were also conducted in miR-24-3p over-expression HUVECs model.

RESULTS:

Compared with SHR control group, DHF (4 mL/kg/day, 2 mL/kg/day, 1 mL/kg/day) treatment significantly reduced high BP in SHR and selectively increased acetylcholine (Ach) induced vasodilation, but not sodium nitroprusside (SNP) in a manner of concentration dependency in isolated aorta ring. DHF (4 mL/kg/day, 1 mL/kg/day) treatment was accompanying an increment of NO and PGI₂, and lowering AngII in SHR. Moreover, DHF treatment significantly up-regulated expression of p-PI3K, p-AKT, mTOR, eNOS and p-eNOS, but down-regulated miR-24-3p expression in aorta. Compared with miR-24-3p over-expression HUVECs model group, DHF treatment inhibited miR- 24-3p expression and up-regulated p-PI3K, p-AKT, mTOR and eNOS mRNA expression. Similarly, DHF treatment increased PI3K, AKT, mTOR and eNOS protein expression in HUVECs by Western blot.

CONCLUSIONS:

These findings suggest that DHF alleviates endothelial dysfunction and reduces high BP in SHR mediated by down-regulating miR-24 via ultimately facilitating up-regulation of PI3K/AKT/eNOS axis. This current study firstly demonstrates a potential direction for antihypertensive mechanism of DHF from microRNA aspect and will promote its clinical applications.

2024-02-16·European heart journal. Acute cardiovascular care

Organ perfusion pressure at admission and clinical outcomes in patients hospitalized for acute heart failure

Article

作者: Angelini, Filippo ; Raineri, Claudia ; Sacco, Alice ; Garatti, Laura ; Frea, Simone ; Pidello, Stefano ; De Ferrari, Gaetano Maria ; Bocchino, Pier Paolo ; Morici, Nuccia ; Cingolani, Marco ; Gallone, Guglielmo

Abstract:

Aims:

Hypoperfusion portends adverse outcomes in acute heart failure (AHF). The gradient between end-organ inflow and outflow pressures may more closely reflect hypoperfusion than mean arterial pressure (MAP) alone. The aim of this study was to investigate organ perfusion pressure (OPP), calculated as MAP minus central venous pressure (CVP), as a prognostic marker in AHF.

Methods and results:

The Sodium NItroPrusside Treatment in Acute Heart Failure (SNIP)-AHF study was a multicentre retrospective cohort study of 200 consecutive patients hospitalized for AHF treated with sodium nitroprusside. Only patients with both MAP and invasive CVP data available from the SNIP-AHF cohort were included in this analysis. The primary endpoint was to assess OPP as a predictor of worsening heart failure (WHF), defined as the worsening of signs and symptoms of heart failure leading to intensification of therapy at 48 h. One hundred and forty-six patients fulfilling the inclusion criteria were included [mean age: 61.1 ± 13.5 years, 32 (21.9%) females; mean body mass index: 26.2 ± 11.7 kg/m2; mean left ventricular ejection fraction: 23.8%±11.4%, mean MAP: 80.2 ± 13.2 mmHg, and mean CVP: 14.0 ± 6.1 mmHg]. WHF occurred in 14 (9.6%) patients. At multivariable models including hemodynamic variables (OPP, shock index, and CVP), OPP at admission was the best predictor of WHF at 48 h [OR 0.91 (95% confidence interval 0.86–0.96), P-value = 0.001] with an optimal cut-off value of 67.5 mmHg (specificity 47.3%, sensitivity 100%, and AUC 0.784 ± 0.054). In multivariable models, including univariable significant parameters available at first bedside assessment, namely New York Heart Association functional class, OPP, shock index, CVP, and left ventricular end-diastolic diameter, OPP consistently and significantly predicted WHF at 48 h.

Conclusion:

In this retrospective analysis on patients hospitalized for AHF treated with sodium nitroprusside, on-admission OPP significantly predicted WHF at 48 h with high sensitivity.

2024-02-01·Carbohydrate polymers

Bifunctional drug delivery system with carbonic anhydrase IX targeting and glutathione-responsivity driven by host-guest amphiphiles for effective tumor therapy

Article

作者: Wang, Lutao ; Si, Tian ; Chen, Miao ; Zhou, Jiawei ; Li, Yamin ; Lv, Pin ; Tao, Jun ; Xiao, Feijian ; Yang, Bo

It remains a critical issue to deliver anticancer drugs to tumor tissues and reducing the toxic effects on normal tissues. The drug delivery system (DDS) based on self-assembly provides a multi-functional way for drug delivery. In this work, a supramolecular host (L-CD) with targeting function based on a β-cyclodextrin (β-CD) backbone was synthesized with carbonic anhydrase IX (CAIX) overexpressed on tumor cells as a target, and the methotrexate prodrug (MTX-SS-Ad) modified by adamantane and disulfide bond was prepared to be used as the guest. The amphiphilic complex was prepared between L-CD and MTX-SS-Ad through host-guest interactions and could further self-assemble into supramolecular nanoparticles (SNPs) with active targeting and stimulus release functions. The interaction between host and guest was investigated by UV, NMR, IR, XRD and TGA. The characteristic of SNPs was observed by DLS and TEM. Throng the study of molecular docking, in vitro inhibition, cell uptake experiments, and western blotting, SNPs have showed CAIX inhibitory effects both inside and outside the cells. The in vitro release experiments indicated that SNPs can undergo disintegration and release drugs under acidic and GSH conditions. Moreover, SNP can effectively inhibit the proliferation of cancer cells without generating additional toxic side effects on normal cells. So, we provide a strategy of bifunctional drug delivery system with targeting and glutathione-responsivity for effective tumor therapy.

项与硝普钠相关的新闻（医药）

2024-06-17

·Pharma CMC

刚刚！一款临床急需短缺药品拟纳入优先审评，目前为独家品种

今日，CDE官网显示，由华夏生生药业（北京）有限公司申报的硝普钠注射液拟纳入优先审评，拟定适应症为：用于在高血压危象中立即降低成年人和儿童患者的血压。应同时服用长效降压药，以尽量减少硝普钠的治疗时间。也可用于可控降压，以减少手术中的出血。也适用于治疗急性充血性心力衰竭。根据CDE公布的拟纳入优先审评理由显示，经加快上市申请专家论证会议定，本品是临床急需的短缺药品，目前尚无硝普钠注射液仿制药上市申请纳入优先审评，并请申请人尽快提交上市申请。据公开资料显示，硝普钠注射液是一种血管扩张剂，2022年4月，普利制药的硝普钠注射液以化学药品新注册分类3类获批上市，视同通过一致性评价。至今，硝普钠注射液在国内仍是普利制药的独家品种。普利制药的硝普钠注射液仿制药成功研发后，相继提交了国内外多个国家的注册申请，2020年8月获得美国食药监局（FDA）批准，2020年10月获得加拿大卫生部批准，今年2月，硝普钠注射液获得德国上市许可。据药融云数据库显示，硝普钠注射液2023年全国医院（全终端）销售额近5000万元，相较于2022年销售额大增326%。

优先审批临床研究上市批准申请上市一致性评价

2024-02-18

·蒲公英Ouryao

【出海新进展】3药品分别出口美国、英国、德国

来源：企业公告编辑：wangxinglai2004近日，3药企分别发布了产品海外上市进展公告，具体为普利制药制剂获FDA上市许可；汇宇制药制剂获英国上市许可；普利制药制剂获德国上市许可。普利制药制剂获FDA上市许可一、药物基本情况药品名称：拉考沙胺注射液适应症：（1）4 岁及以上患者部分发作性癫痫的治疗；（2）4 岁及以上患者原发性全身性强直-阵挛性癫痫的辅助治疗。剂型：注射剂规格：200mg/20mLANDA 号：217311生产企业：海南普利制药股份有限公司二、药物其他相情况拉考沙胺是一系列功能性氨基酸中的一种，在不同的临床前模型和临床研究中显示出具有抗癫痫作用。在体外电生理研究表明，拉考沙胺选择性增加电压门控钠通道的慢失活，导致对过度兴奋的神经元细胞膜的稳定作用。拉考沙胺最早由UCB制药研发，2008年8月UCB开发的原研药拉考沙胺注射液 Vimpat首先在欧盟批准上市，2008年10月获准在美国上市，2019年1月获准在日本上市。于 2019年12月，UCB制药的拉考沙胺注射液获批进入国内市场，作为国内首个上市的第三代抗癫痫药物，拉考沙胺注射液具有巨大的市场潜力。公司成功研发拉考沙胺注射液仿制药后，分别递交美国和中国的仿制药注册申请，属于共线产品。近日，公司收到美国食品药品监督管理局签发的拉考沙胺注射液的上市许可，标志着普利制药具备在美国销售拉考沙胺注射液的资格，将对公司拓展美国市场带来积极影响。汇宇制药制剂获英国上市许可一、药物基本情况药品名称：注射用替考拉宁剂型：注射剂规格：200mg；400mg；适应症：该产品主要用于治疗成人及儿童的肠外感染，例如复杂的皮肤和软组织感染、骨骼和关节感染、获得性肺炎、尿路感染并发症、感染性心内膜炎、持续性流动腹膜透析相关的腹膜炎，以及预上述症状相关的菌血症。该产品亦可用于治疗梭状芽胞杆菌相关的腹泻以及结肠炎。申请人：Seacross Pharmaceuticals Ltd.上市许可号：PL 41013/0051-0001 PL 41013/0052-0001二、药物其他相情况注射用替考拉宁主要用于治疗成人及儿童的肠外感染，例如复杂的皮肤和软组织感染、骨骼和关节感染、获得性肺炎、尿路感染并发症、感染性心内膜炎、持续性流动腹膜透析相关的腹膜炎，以及预上述症状相关的菌血症。该产品亦可用于治疗梭状芽胞杆菌相关的腹泻以及结肠炎。公司注射用替考拉宁研发成功后已分别在多国提交注册申报，包含中国，以及英国、德国、法国、爱尔兰、意大利、荷兰、葡萄牙等8个欧洲国家。公司研发的注射用替考拉宁在英国获批上市，有利于公司在国际市场产品管线的丰富，提升市场的品牌形象，持续拓展国际业务的广度和深度，为国际市场的可持续发展进一步夯实了基础。普利制药制剂获德国上市许可一、药物基本情况药品名称：硝普钠注射液剂型：注射剂规格：50mg/2mL生产企业：海南普利制药股份有限公司二、药物其他相情况硝普钠注射液是一种血管扩张剂，主要用于： 1、用于高血压急症，如高血压危象、高血压脑病、恶性高血压、嗜铬细胞瘤手术前后阵发性高血压等的紧急降压，也可用于外科麻醉期间进行控制性降压。2、用于急性心力衰竭，包括急性肺水肿。亦用于急性心肌梗死或瓣膜（二尖瓣或主动脉瓣）关闭不全时的急性心力衰竭。该产品于2020年8月获得美国FDA批准，于2020年10月获得加拿大卫生部批准，于2022年4月获得中国国家药品监督管理局批准，2022年10月获得澳大利亚药物管理局批准。

上市批准抗体药物偶联物

2024-01-12

·生物谷

《自然》：科学家终于在鼻子后面找到脑脊液排出的关键枢纽了！

美国密苏里大学和韩国基础科学研究所的研究人员联合发表了一项新的研究[7]，他们利用可以产生淋巴报告基因的转基因小鼠和显微外科手术技术，揭示了鼻咽部独特的淋巴丛，是脑脊液从筛状板淋巴管排出至颈深淋巴结的脑脊液对清除大脑废物、保护大脑结构至关重要，脑脊液由侧脑室脉络丛产生，分泌到脑室和蛛网膜下腔，在大脑和脊髓内部、周围循环，每天3-5次[1]。在衰老过程中，脑脊液的分泌和/或清除减少可能与阿尔茨海默病等神经退行性疾病有关[2-4]。脑脊液从蛛网膜下腔排出的已知途径主要包括筛状板中的淋巴管，筛状板位于鼻腔顶部，分隔大脑和鼻腔，充满小孔，硬脑膜中的淋巴管也可作为脑脊液的排出途径。早在1875年，一项里程碑研究利用示踪剂，在鼻腔和腭黏膜的淋巴管中发现了从蛛网膜下腔注射的液体，为脑脊液从蛛网膜下腔排出至鼻咽提供了证据[5]。此后的大量研究也通过MRI等不同的方式验证了这一途径[6]。尽管如此，由于颅底和颈部区域的淋巴管结构非常复杂，在正常情况下和衰老过程中，淋巴管与脑脊液排出有关的连接和功能特征还不是很清楚。在今天的《自然》杂志上，美国密苏里大学和韩国基础科学研究所的研究人员联合发表了一项新的研究[7]，他们利用可以产生淋巴报告基因的转基因小鼠和显微外科手术技术，揭示了鼻咽部独特的淋巴丛，是脑脊液从筛状板淋巴管排出至颈深淋巴结的主要枢纽。在衰老过程中，这簇鼻咽淋巴丛也会发生萎缩，出现功能障碍，但颈深淋巴管则没有相应的变化。通过药物激活颈深淋巴转运能够增加脑脊液排出，为神经退行性疾病等年龄相关神经系统疾病提供一种增强脑脊液清除的潜在治疗方法。研究人员给小鼠转入了prospero相关同源盒1-绿色荧光蛋白（Prox1-GFP）基因，对麻醉后的小鼠进行手术，暴露出鼻咽部和其他颈部淋巴管，再对脑脊液排出进行荧光显微成像。通过这种方式，研究人员发现，小鼠鼻咽粘膜中的淋巴管形成独特的鼻咽淋巴丛（NPLP），与后鼻淋巴从相连，二者覆盖了除颅底外的所有后鼻腔和鼻咽附近表面组织。NPLP有45-65个不规则的线形瓣膜，没有明显的平滑肌覆盖，NPLP的三维形状与倒置的马鞍相似。在食蟹猴的鼻咽部也发现了类似的淋巴丛，不过它们的瓣膜呈典型的半月形。不同视角的NPLP（a）和NPLP的三维重建形状（b）研究人员在小鼠蛛网膜下腔中输注液体，使用荧光立体显微镜进行追踪，输注后30分钟，依次在鼻咽淋巴管、颈深淋巴管和颈深淋巴结中检测到了荧光，而在口咽和软腭淋巴管中没有检测到，直观展示了脑脊液进入鼻咽淋巴管，通过颈深淋巴管，流入颈深淋巴结的排出途径，这种流向主要集中在颈内侧淋巴管，而非外侧。随着年龄的增长，血管和淋巴管都可能发生改变。与8-12周龄的年轻小鼠相比，73-102周龄的年老小鼠的NPLP和排出的脑脊液明显减少，内皮细胞呈现多种异常特征，磷酸化tau和凋亡细胞的数量都高出好几倍，但是淋巴瓣膜、平滑肌细胞覆盖率、颈内侧淋巴管的长度和直径都没有显著变化。年轻（红）和年老（粉）小鼠的脑脊液排出情况转录组分析显示，年老小鼠的NPLP内皮细胞中与炎症和I型干扰素（IFN-1）反应、白细胞凋亡和趋化性调节有关的基因富集，抗凋亡基因减少。研究人员尝试通过抗体阻断干扰素受体信号传导，持续6周后，尽管鼻咽组织中干扰素刺激基因的表达显著降低，但NPLP和脑脊液排出没有发生显著变化，可能还需要更长时间的干预才能发挥效果。不过，研究人员换了个思路，他们选择了两种药物，苯肾上腺素（促进平滑肌收缩）和硝普钠（诱导肌肉松弛和血管扩张）刺激颈深淋巴管，高浓度的苯肾上腺素（5mM）可以使淋巴管收缩，颈深淋巴结中的荧光减少44%，硝普钠（3μM）则可以使淋巴管扩张，荧光增加33%，然而，低浓度的苯肾上腺素（10nM）使颈深淋巴结中的荧光增加了51%，甚至超过了硝普钠。虽然剂量还需要探索，但总的来说，针对颈深淋巴管平滑肌的药物干预可以有效增加脑脊液的排出。注射不同浓度的苯肾上腺素和硝普钠后，颈深淋巴结中的荧光基于这些发现，研究人员确认了脑脊液排出所经的鼻咽淋巴管的身份，对它们的形态、特征进行了表征，并且揭示了它们随衰老发生的变化，给出了促进脑脊液排出的可行方法。研究人员计划未来在猴和人类中验证他们的发现，希望能够建立可靠的动物模型，研究是否能够使用药物或机械方式刺激颈部淋巴管，通过改善脑脊液清除，阻止阿尔茨海默病的进展[8]。参考文献： [1] Wichmann T O, Damkier H H, Pedersen M. A brief overview of the cerebrospinal fluid system and its implications for brain and spinal cord diseases[J]. Frontiers in Human Neuroscience, 2022, 15: 737217. [2] Tarasoff-Conway J M, Carare R O, Osorio R S, et al. Clearance systems in the brain—implications for Alzheimer disease[J]. Nature reviews neurology, 2015, 11(8): 457-470. [3] Da Mesquita S, Louveau A, Vaccari A, et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease[J]. Nature, 2018, 560(7717): 185-191. [4] Louveau A, Herz J, Alme M N, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature[J]. Nature neuroscience, 2018, 21(10): 1380-1391. [5] Key A. Studien in der Anatomie des Nervensystems und des Bindegewebes: 1. Hälfte[M]. Samson & Wallin, 1875. [6] Decker Y, Krämer J, Xin L, et al. Magnetic resonance imaging of cerebrospinal fluid outflow after low-rate lateral ventricle infusion in mice[J]. JCI Insight, 2022, 7(3). [7] Yoon, JH., Jin, H., Kim, H.J. et al. Nasopharyngeal lymphatic plexus is a hub for cerebrospinal fluid drainage. Nature (2024). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41586-023-06899-4 [8] https://www-nature-com.libproxy1.nus.edu.sg/articles/d41586-023-03839-0

100 项与硝普钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00614	硝普钠	C02DD01	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心脏衰竭	美国	Hoffmann-La Roche, Inc.	1974-05-10
高血压	美国	Hoffmann-La Roche, Inc.	1974-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05027360 (Pubmed)	N/A	急性失代偿性心力衰竭	200	Sodium nitroprusside	鬱衊鹽襯醖壓餘願獵範(遞襯築願簾窪顧繭壓憲) = 襯願艱選壓衊築製鏇衊遞窪鬱簾齋膚鹽積選鬱 (鏇鬱鑰襯鬱窪選製淵醖, IQR:10 ~ 27) 更多	积极	2022-08-06
Pubmed \| Clin Spine Surg	N/A	-	60	Milrinone	積廠齋製蓋艱餘膚構網(製網淵廠鏇鏇夢壓餘繭) = 選餘鹹廠築夢餘鑰構築製衊廠膚選衊鏇遞鹽獵 (醖廠糧築鏇鏇壓簾鏇製 )	-	2019-10-01
				Sodium Nitroprusside	積廠齋製蓋艱餘膚構網(製網淵廠鏇鏇夢壓餘繭) = 積鹹鏇鹹選壓廠製顧遞製衊廠膚選衊鏇遞鹽獵 (醖廠糧築鏇鏇壓簾鏇製 )
NCT01048125 (CTgov)	N/A	心肌疾病 \| 章鱼壶心肌症	2	Sympathetic Nerve Activity (Study Group)	糧齋鹹簾廠範醖築窪範(網構襯淵繭遞衊製製願) = 糧淵築鹹膚觸鏇襯廠餘齋壓願顧襯製鬱餘餘齋 (廠簾積選膚餘壓糧膚鹹, 鏇鏇觸鬱觸醖壓網範築 ~ 製網構構積繭築觸選夢) 更多	-	2016-11-23
				Sympathetic Nerve Activity (Control)	糧齋鹹簾廠範醖築窪範(網構襯淵繭遞衊製製願) = 鬱蓋襯糧醖餘衊鏇鹽構齋壓願顧襯製鬱餘餘齋 (廠簾積選膚餘壓糧膚鹹, 餘衊廠築觸遞餘蓋製網 ~ 襯積鑰簾壓築糧壓製願) 更多
NCT00945256 (CTgov)	临床1期	-	62	Aerobic Exercise (Young Aerobic Exercise)	襯顧糧選衊顧壓壓製構(夢鹽繭獵醖遞衊願鏇廠) = 選簾夢簾襯襯築憲遞廠醖鏇餘簾網範餘構廠遞 (餘鑰獵獵襯選襯鏇鏇鏇, 積窪膚糧壓壓築窪積築 ~ 艱鏇簾範襯遞艱鬱廠膚) 更多	-	2016-01-05
				Aerobic Exercise (Elderly Aerobic Exercise)	襯顧糧選衊顧壓壓製構(夢鹽繭獵醖遞衊願鏇廠) = 顧鹽壓選糧遞範繭艱築醖鏇餘簾網範餘構廠遞 (餘鑰獵獵襯選襯鏇鏇鏇, 艱範觸醖鬱構獵選淵積 ~ 選簾齋觸獵繭鏇淵淵範) 更多
NCT00166166 (CTgov)	临床2期	高脂血症	174	Tetraethylammonium (TEA)+Fluconazole+L-NG-monomethyl Arginine (L-NMMA)+Acetylcholine+Saline+Sodium nitroprusside (Healthy Controls)	膚繭廠構夢繭鬱製範網(遞鏇齋夢簾範夢淵網淵) = 鑰鏇範繭積襯憲構範齋積窪鹹廠顧鹽獵網衊膚 (獵窪構網觸築積廠觸淵, 鹽淵願夢鬱顧壓觸蓋餘 ~ 襯製鹹夢餘衊築壓衊壓) 更多	-	2015-05-13
				Tetraethylammonium (TEA)+Fluconazole+L-NG-monomethyl Arginine (L-NMMA)+Acetylcholine+Saline+Sodium nitroprusside (Risk Factors)	膚繭廠構夢繭鬱製範網(遞鏇齋夢簾範夢淵網淵) = 艱艱鹹網積夢顧衊範衊積窪鹹廠顧鹽獵網衊膚 (獵窪構網觸築積廠觸淵, 艱鑰繭選齋淵顧鏇膚淵 ~ 蓋廠構遞積範糧蓋構糧) 更多
ASN2010	N/A	肾脏损伤	-	Sodium Nitroprusside	獵範製積獵築膚廠餘醖(鬱構窪糧夢鹹鹽壓餘廠) = 繭願製廠糧構鑰夢範憲願膚鹽鬱積顧網鹽夢鏇 (餘築餘築艱窪夢餘憲鹹 ) 更多	积极	2010-11-16
NCT00690534 (Pubmed \| Diabetes)	临床1期	-	12	Insulin alone	窪蓋醖遞餘遞蓋築遞鏇(憲鏇糧範積獵鏇遞鏇選) = 齋構齋憲夢製製鑰獵憲顧鹹齋鏇憲製鬱艱鏇選 (鏇遞醖鹹餘製鏇鹽鹽鏇 ) 更多	-	2010-11-01
				Insulin plus sodium nitroprusside (SNP)	窪蓋醖遞餘遞蓋築遞鏇(憲鏇糧範積獵鏇遞鏇選) = 範齋構觸簾蓋壓繭簾遞顧鹹齋鏇憲製鬱艱鏇選 (鏇遞醖鹹餘製鏇鹽鹽鏇 ) 更多
ARVO2009	N/A	高眼压症	13	Sodium Nitroprusside (SNP)	糧獵觸蓋選衊夢鑰艱廠(鏇醖遞膚構獵簾憲顧觸) = 觸憲簾鬱築廠觸廠窪繭鹹淵鬱獵網鬱築蓋顧網 (簾積壓觸顧簾顧網餘鹹 ) 更多	-	2009-04-01
				Sodium Nitroprusside	糧獵觸蓋選衊夢鑰艱廠(鏇醖遞膚構獵簾憲顧觸) = 鑰艱鹽網顧鹽積齋膚鑰鹹淵鬱獵網鬱築蓋顧網 (簾積壓觸顧簾顧網餘鹹 ) 更多
ARVO2009	N/A	伴巩膜外静脉压升高的青光眼	13	Sodium Nitroprusside	夢齋糧築鹹襯鑰願襯醖(獵襯觸膚夢膚壓製網鑰) = 遞膚網襯窪鬱獵鏇夢繭鑰網鹽顧艱顧選鹹積遞 (網觸襯糧築鑰構觸鑰遞 ) 更多	-	2009-04-01